CASE HUB ARCHIVED—this archived case hub reflects the position at the date of the judgment of 25 March 2021; it is no longer maintained. See further, timeline commentary and related/similar cases. Case facts Outline Cases C- 586/16 Sun Pharmaceutical Industries and Ranbaxy (UK) v Commission, C- 588/16 Generics (UK) v Commission, C- 591/16 P Lundbeck v Commission, C- 601/16 Arrow Group and Arrow Generics v Commission, C- 611/16 Xellia Pharmaceuticals and Alpharma v Commission and C- 614/13 Merck v Commission—appeals to the Court of Justice against the General Court’s judgments in Cases T- 460/13, T- 467/13, T-469/13, T- 470/13, T-471/13 and T- 472/13 which dismissed actions for annulment of the Commission’s decision of 19 June 2013 finding four infringements of Article 101 TFEU and Article 53 EEA Agreement and imposing fines totalling €146m